Core Framework & Diagram How Do T Cells Kill Cancer Cells?
July 14, 20261 Min Read How Do NK Cells Kill Abnormal Cells?
July 14, 2026When the immune system decides to kill a cancer cell, how exactly does a T cell do it?
—— Precision cellular surgery: making a cancer cell collapse from within — without touching surrounding normal tissue.
I. Why T cell killing is more precise than chemotherapy
Chemotherapy kills cancer cells based on a relatively blunt principle: attacking rapidly dividing cells. Most cancer cells divide fast, so chemotherapy can kill them. But chemotherapy can't distinguish 'rapidly dividing cancer cells' from 'rapidly dividing normal cells' — bone marrow (producing blood cells), digestive tract mucosa, and hair follicles are all damaged by chemotherapy because they normally update rapidly. This is the source of chemotherapy side effects (hair loss, nausea, white cell reduction).
CD8+ cytotoxic T cells (CTL) operate on a completely different principle: 'identity-verified precision strike.' First, T cell receptors (TCR) recognize specific peptides on the target cell's MHC-I (for cancer cells, the neoantigen peptide). Only after this 'identity confirmation' is the killing program initiated. Killing happens in a highly directional manner at the direct contact interface (immunological synapse) — toxic substances are 'injected' into the target cell, not dispersed into the surrounding environment.
This design achieves 'precision strike': cancer cells expressing this specific MHC-I/neoantigen combination are killed; surrounding normal cells not expressing this combination are safe. Of course, this precision has costs: T cells must first 'know' this specific target antigen. Encountering a new type of cancer for the first time takes time to build memory. And if cancer cells evade by downregulating MHC-I, T cells lose their recognition targets. Understanding this mechanism clarifies the core logic of tumor immunotherapy: not making T cells 'stronger' — but helping T cells more effectively 'find targets' (neoantigen vaccines) and 'maintain attack state' (PD-1 inhibitors relieving exhaustion).
2. The immunological synapse: a temporary, highly ordered killing interface
When a CD8+ T cell's TCR recognizes a specific peptide on the target cell's MHC-I and receives sufficiently strong activation signals, a rapid and precise molecular rearrangement occurs at the cell contact surface: the formation of an immunological synapse.
The immunological synapse isn't random membrane contact — it's a highly ordered supramolecular structure specifically designed for killing. Different molecular types arrange in concentric ring patterns at the contact surface: TCR-MHC complexes, CD8 co-receptors, and various activation signaling molecules cluster at the center (the signal transduction core); integrin adhesion molecules aggregate at the periphery, firmly 'welding' the T cell and target cell together; and the secretory zone precisely faces the target cell membrane, ensuring directional release of toxic granules.
This directionality is the immunological synapse's most important function: ensuring perforin and granzyme are precisely 'aimed' at the target cell rather than leaking into the extracellular environment. If granzyme dispersed extracellularly, it would cause non-specific damage to all surrounding cells — unacceptable 'friendly fire.' The immunological synapse strictly limits the killing action to the direct T cell-target cell contact surface, achieving 'point delivery' of killing signals — the key structural design enabling T cell precision without harming bystanders.
Immunological synapse formation typically completes within minutes; the entire killing process takes approximately five to ten minutes, then the T cell detaches from the target cell and continues searching for the next target. The same effector CTL can sequentially kill multiple target cells — like a reusable precision weapon, extremely efficient.
3. Perforin and granzyme: the molecular weapons for internal destruction
After immunological synapse formation, CD8+ T cells release two core killing weapons pre-stored in cytoplasmic granules: perforin and granzyme B.
Perforin
A protein structurally similar to the complement system's membrane attack complex (MAC). It polymerizes on the target cell membrane, forming transmembrane pore channels. These pores serve two functions: directly physically disrupting membrane integrity (massive poration causes osmotic imbalance, cell swelling and lysis — a rapid necrotic death mechanism at high perforin concentrations); and more importantly, as a channel for granzyme B to enter the target cell (the primary mechanism at lower perforin concentrations).
Granzyme B
A serine protease that, once it enters the target cell through perforin channels, activates the caspase (cysteine aspartyl protease) cascade — particularly directly cleaving caspase-3 (the 'executor' of cell apoptosis), triggering the cell's orderly programmed death (apoptosis).
Apoptosis is a 'quiet' form of cell death: the cell compacts in an orderly manner, DNA is systematically cut into fragments, cell membrane folds inward forming 'apoptotic bodies,' ultimately cleanly engulfed by nearby macrophages without releasing any pro-inflammatory signals into surroundings. This completely contrasts with necrosis (cells rupture disorderly, contents leak out, trigger inflammation).
T cell-induced target cell apoptosis (rather than necrosis) is another elegant design: killing cancer cells while not triggering additional local inflammation, not stimulating the tumor microenvironment — allowing clearance work to complete cleanly and in an orderly manner. This is precisely where the 'precision surgery' metaphor is most apt.
4. CAR-T cells: the revolutionary treatment that installs a navigation system for T cells
Understanding CD8+ T cells' natural cancer-killing mechanism lets us understand one of the most important tumor immunotherapy technologies in recent years: CAR-T cells.
Under natural conditions, CD8+ T cells recognizing cancer cells depends on cancer cells presenting neoantigens via MHC-I — requiring cancer cells' MHC-I to be normally expressed (while many cancer cells downregulate MHC-I to evade), and requiring T cells' TCR to happen to recognize specific neoantigens (a relatively low-probability event).
CAR-T (Chimeric Antigen Receptor T cell) therapy solves both limitations. Through genetic engineering, researchers fuse a 'single-chain antibody' binding domain specifically recognizing a tumor cell surface protein (tumor-associated antigen, like CD19 on B cells) with T cell activation signal domains, creating a chimeric antigen receptor (CAR). This artificial receptor is installed on the patient's own T cells, giving T cells a completely new, MHC-I-independent 'navigation system' — as long as tumor cells express CD19, regardless of MHC-I status, CAR-T cells can recognize and kill them using the same perforin/granzyme mechanism.
CAR-T therapy targeting CD19 has achieved remarkable efficacy in relapsed/refractory B cell leukemia and lymphoma — some previously essentially untreatable patients achieved complete remission and even cure. This is the paradigm for combining T cells' precise killing capacity with antibodies' targeting recognition capacity, representing a revolution in cellular immunotherapy.
CAR-T therapy's main challenges include: severe cytokine release syndrome (CRS — massive T cell activation releasing large amounts of cytokines), target antigen expression on normal cells (CD19 also on normal B cells, causing B cell depletion), and CAR-T cell penetration and persistence issues in solid tumors. These challenges are among the most active areas of current cancer immunotherapy research.
5. T cell exhaustion: when sustained tumor pressure causes killing power to fade
In the tumor microenvironment, CD8+ T cells face a serious challenge: prolonged, sustained antigen stimulation (tumor cells continuously proliferating, continuously presenting the same antigens) causes T cells to enter an 'exhaustion' state.
Exhausted T cells are a state of gradually impaired function — not simply 'dead,' but alive yet progressively less battle-capable. Exhausted T cell characteristics: PD-1, LAG-3, TIM-3, and other inhibitory receptor expression continuously rises; effector functions (perforin/granzyme production and release) progressively weaken; proliferative capacity declines — even facing antigen stimulation, unable to adequately expand.
The tumor microenvironment is a 'forge' for producing T cell exhaustion: tumor cells' continuously secreted TGF-β, IL-10, and other inhibitory factors; continuously activated inhibitory receptor ligands (PD-L1 etc.); plus the hypoxic and nutrient-deprived microenvironment, collectively push effector T cells entering tumors toward exhaustion.
This is why PD-1 inhibitors can effectively treat some cancers: they don't make T cells 'stronger' — they block the PD-1 signal that was progressively exhausting T cells, preventing the perforin/granzyme killing program from being prematurely shut off, maintaining T cells' sustained effective killing activity. For deeply exhausted T cells, PD-1 inhibitors' effects are limited — why combination strategies targeting LAG-3, TIM-3, and other checkpoints with multi-target inhibitors are becoming active research areas.
Understanding T cell exhaustion clarifies why 'enhancing immunity' is the wrong framework for treating cancer — T cells in tumors aren't too few, they're too tired. The correct framework is: help them recover from fatigue.
Frequently Asked Questions